News coverage about Quest Diagnostics (NYSE:DGX) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Quest Diagnostics earned a news impact score of 0.21 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 46.4953561681238 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the media headlines that may have effected Accern’s rankings:

Quest Diagnostics (NYSE:DGX) traded down 0.84% on Thursday, hitting $105.61. The stock had a trading volume of 690,640 shares. The company has a market cap of $14.41 billion, a price-to-earnings ratio of 21.28 and a beta of 0.69. Quest Diagnostics has a 52-week low of $79.12 and a 52-week high of $112.97. The company has a 50 day moving average price of $108.92 and a 200-day moving average price of $102.93.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.42 by $0.13. The business had revenue of $1.94 billion during the quarter, compared to analysts’ expectations of $1.94 billion. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.34 EPS. On average, equities research analysts predict that Quest Diagnostics will post $5.70 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, July 24th. Stockholders of record on Monday, July 10th were issued a $0.45 dividend. The ex-dividend date was Thursday, July 6th. This represents a $1.80 annualized dividend and a dividend yield of 1.70%. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.29%.

A number of research analysts have weighed in on the company. UBS AG reissued a “buy” rating and issued a $115.00 target price (up previously from $102.00) on shares of Quest Diagnostics in a report on Tuesday, April 25th. Zacks Investment Research raised Quest Diagnostics from a “hold” rating to a “buy” rating and set a $122.00 target price on the stock in a report on Tuesday, June 6th. Mizuho reissued a “buy” rating and issued a $90.00 target price (down previously from $103.00) on shares of Quest Diagnostics in a report on Friday, April 14th. BidaskClub raised Quest Diagnostics from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 29th. Finally, ValuEngine raised Quest Diagnostics from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. Two analysts have rated the stock with a sell rating, eight have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $109.62.

COPYRIGHT VIOLATION NOTICE: “Quest Diagnostics (NYSE:DGX) Getting Somewhat Positive News Coverage, Report Shows” was originally published by Daily Political and is owned by of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/10/quest-diagnostics-nysedgx-getting-somewhat-positive-news-coverage-report-shows.html.

In other news, Director Jeffrey M. Leiden sold 1,304 shares of the business’s stock in a transaction dated Thursday, July 27th. The stock was sold at an average price of $108.73, for a total value of $141,783.92. Following the completion of the transaction, the director now owns 6,296 shares of the company’s stock, valued at approximately $684,564.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Catherine T. Doherty sold 59,762 shares of the business’s stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $107.55, for a total value of $6,427,403.10. Following the completion of the transaction, the senior vice president now directly owns 78,582 shares of the company’s stock, valued at approximately $8,451,494.10. The disclosure for this sale can be found here. In the last three months, insiders sold 61,362 shares of company stock valued at $6,600,758. Insiders own 1.50% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.